110 related articles for article (PubMed ID: 30773105)
21. Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
Aghel N; Delgado DH; Lipton JH
Leukemia; 2018 Oct; 32(10):2095-2104. PubMed ID: 30201984
[TBL] [Abstract][Full Text] [Related]
22. Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.
Hochhaus A
Ann Oncol; 2006 Sep; 17 Suppl 10():x274-9. PubMed ID: 17018738
[No Abstract] [Full Text] [Related]
23. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
[No Abstract] [Full Text] [Related]
24. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
Wang W; Chen Z; Hu Z; Yin CC; Li S; Bai S; Bueso-Ramos CE; Medeiros LJ; Hu S
Blood Cancer J; 2016 Nov; 6(11):e490. PubMed ID: 27813536
[No Abstract] [Full Text] [Related]
25. Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead.
Amitai I; Leader A; Raanani P
Acta Haematol; 2016; 136(1):43-4. PubMed ID: 27160309
[No Abstract] [Full Text] [Related]
26. Peripheral neuropathy as an adverse effect of imatinib therapy.
Chakupurakal G; Etti RJ; Murray JA
J Clin Pathol; 2011 May; 64(5):456. PubMed ID: 21278395
[No Abstract] [Full Text] [Related]
27. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
28. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
Takahashi N
Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
[No Abstract] [Full Text] [Related]
29. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
30. [Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Saito M; Izumiyama K; Mori A; Irie T; Tanaka M; Morioka M; Saga A; Musashi M; Kato T; Meguro T; Tanino M
Rinsho Ketsueki; 2014 Jan; 55(1):130-2. PubMed ID: 24492046
[TBL] [Abstract][Full Text] [Related]
31. Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?
Cristóbal I; Manso R; González-Alonso P; Rojo F; García-Foncillas J
Leukemia; 2015 Oct; 29(10):2117. PubMed ID: 26283451
[No Abstract] [Full Text] [Related]
32. [Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor].
Ohno R
Nihon Rinsho; 2001 Dec; 59(12):2389-94. PubMed ID: 11766344
[TBL] [Abstract][Full Text] [Related]
33. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia.
Salie R; Silver RT
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):331-5. PubMed ID: 21030345
[TBL] [Abstract][Full Text] [Related]
34. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
O'Dwyer ME; Druker BJ
Curr Opin Oncol; 2000 Nov; 12(6):594-7. PubMed ID: 11085460
[TBL] [Abstract][Full Text] [Related]
35. [Can chronic myeloid leukemia be cured by tyrosine kinase inhibitor?].
Li MQ; Liu ZG
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):725-8. PubMed ID: 23978030
[No Abstract] [Full Text] [Related]
36. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.
Hosoya K; Mochinaga S; Emoto A; Yokoo H; Tokushima H; Egoshi M; Sueoka-Aragane N; Kimura S
Int J Clin Oncol; 2015 Dec; 20(6):1203-10. PubMed ID: 26002407
[TBL] [Abstract][Full Text] [Related]
37. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
38. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
39. TKIs and transplant for chronic myeloid leukemia.
Litzow MR
Leuk Res; 2010 Feb; 34(2):137-8. PubMed ID: 19651441
[No Abstract] [Full Text] [Related]
40. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
